Poltreg S.A. Logo

Poltreg S.A.

Pioneering T-regulatory cell therapies for autoimmune diseases like diabetes, MS, and ALS.

PTG | WAR

Overview

Corporate Details

ISIN(s):
PLPLTRG00012 (+2 more)
LEI:
259400XSAJTERJ42VZ86
Country:
Poland
Address:
GDAŃSK BOTANICZNA 20, 80-298 GDAŃSK
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Poltreg S.A. is a clinical-stage biotechnology company pioneering the development of T-regulatory cell (Treg) therapies for autoimmune diseases. The company aims to establish Tregs as a new class of disease-modifying therapeutics. Its advanced pipeline features several clinical assets, with the lead candidate, PTG-007, being developed for Type-1 Diabetes and Multiple Sclerosis (MS). Poltreg is also advancing engineered cell therapies, including first-in-class CAR-Treg programs for MS and Amyotrophic Lateral Sclerosis (ALS). Leveraging its own manufacturing facilities and extensive experience, the company was the first to administer a Treg-based therapy to a patient.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-10 17:09
Audit Report / Information
Raport biegłego rewidenta z przeglądu sprawozdania finansowego
Polish 233.4 KB
2025-09-10 17:09
Management Discussion and Analysis
Sprawozdanie Zarządu z działalności za okres 6 miesięcy zakończony dnia 30 czer…
Polish 2.8 MB
2025-09-10 17:09
Interim Report
Sprawozdanie finansowe za okres 6 miesięcy zakończony dnia 30 czerwca 2025 roku
Polish 3.4 MB
2025-09-03 10:39
Regulatory News Service
Warunkowe przyznanie patentu przez Koreański Urząd Patentowy w projekcie terapi…
Polish 1.7 KB
2025-08-04 14:37
Legal Proceedings Report
Podanie pierwszemu pacjentowi terapii w ramach badania klinicznego fazy II w pr…
Polish 2.8 KB
2025-07-31 08:50
Legal Proceedings Report
Otrzymanie od FDA protokołu z podsumowaniem spotkania pre-IND - Content (PL)
Polish 2.0 KB
2025-07-29 14:05
Regulatory News Service
Otrzymanie Certyfikatu Dobrej Praktyki Wytwarzania od Głównego Inspektora Farma…
Polish 1005 bytes
2025-06-23 15:30
Regulatory News Service
Warunkowe przyznanie europejskiego patentu dotyczącego metody ekspansji ex vivo…
Polish 884 bytes
2025-06-13 15:56
Foreign Filer Report
Rejestracja spółki zależnej Immuthera w USA - Content (PL)
Polish 784 bytes
2025-05-21 12:30
Declaration of Voting Results & Voting Rights Announcements
Wykaz akcjonariuszy posiadających co najmniej 5% głosów na Zwyczajnym Zgromadze…
Polish 2.3 KB
2025-05-20 22:12
M&A Activity
Warunkowe przyznanie patentu przez Australijski Urząd Patentowy w projekcie ter…
Polish 1.4 KB
2025-05-20 22:12
M&A Activity
Warunkowe przyznanie patentu przez Australijski Urząd Patentowy w projekcie ter…
Polish 1.3 KB
2025-05-20 15:45
Remuneration Information
Sprawozdanie RN o wynagrodzeniach
Polish 1.2 MB
2025-05-20 15:45
Post-Annual General Meeting Information
Podjęte Uchwały
Polish 184.3 KB
2025-05-20 15:45
Post-Annual General Meeting Information
Treść uchwał podjętych przez Zwyczajne Walne Zgromadzenie PolTREG S.A. w dniu 2…
Polish 729 bytes

Automate Your Workflow. Get a real-time feed of all Poltreg S.A. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Poltreg S.A.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Poltreg S.A. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
VENTURE LIFE GROUP PLC Logo
Develops, manufactures, and distributes consumer self-care products and medical devices globally.
United Kingdom VLG
Vetoquinol SA Logo
Develops and markets veterinary drugs and products for companion animals and livestock worldwide.
France VETO
Vifor Pharma AG Logo
A global leader in specialty pharmaceuticals for iron deficiency and nephrology.
Switzerland VIFN
ViGenCell Inc. Logo
Developing T-cell immune therapies to treat cancer and other incurable diseases.
South Korea 308080
Virbac Logo
Develops animal health pharma, vaccines & diagnostics for vets, farmers & pet owners globally.
France FR000
ViroGates A/S Logo
Develops suPAR diagnostic tests for inflammation risk assessment in acute care and longevity.
Denmark VIRO
Vistin Pharma Logo
A leading global producer of Metformin Hydrochloride for the global healthcare market.
Norway VISTN
Vita 34 AG Logo
A cell bank storing umbilical cord stem cells as biological insurance for families' future health.
Germany V3V
Vivoryon Therapeutics N.V. Logo
Developing first-in-class small molecule therapies for age-related and kidney diseases.
Germany VVY
Develops innovative, non-narcotic drugs for pain and central nervous system (CNS) diseases.
South Korea 082800

Talk to a Data Expert

Have a question? We'll get back to you promptly.